文献速递基础与转化研究临床试验与 GCP流行病学与生物统计

早期药物研发中评估生物标志物预测性的适应性试验设计

Adaptive Trial Designs for Assessing Predictiveness of a Biomarker in Early Phase Drug Development.
PubMed 文献 · Stat Med · 2026-01-01

针对小样本且治疗组间样本量不平衡时生物标志物预测效应检验效能有限的问题,提出一种适应性设计,通过期中分析对预测效应进行正式评估,并可根据结果提前声明预测性、因缺乏证据终止或进入扩展阶段增加样本以提高最终分析效能。模拟研究评估了该设计在不同决策边界和扩展规模下的统计效能、I类错误控制及期中决策特征。

要点

  • 期中分析可提前评估生物标志物预测效应,避免样本不足导致效能低下。
  • 根据期中结果可提前声明预测性、因无效终止或进入扩展阶段增加样本。
  • 设计需控制I类错误率并考虑生物标志物分布未知的影响。

核心结论

  • 所提出的适应性设计可在小样本条件下通过期中分析改善对生物标志物预测效应的检验效能,并支持统计上高效且校准良好的决策。

研究设计与样本

  • 方法学论文,提出一种用于评估生物标志物预测效应的适应性设计框架,并通过模拟研究评估其性能。
  • 模拟研究考察了不同设计配置(决策边界和扩展规模改变)及不同场景(生物标志物真实预测效应和预后效应变化)下的期中与最终分析特性。

主要发现

  • 期中分析框架可在原定样本量下对生物标志物预测效应进行预先计划的评估,该样本量可能因患者数量有限而效能不足。
  • 根据期中结果,试验可(i)已有足够证据声明生物标志物具有预测性,(ii)因明确缺乏预测效应证据而提前终止,或(iii)进入扩展阶段招募额外患者队列以提高最终分析效能。
  • 模拟研究评估的指标包括统计效能、I类错误控制和期中决策特征。

临床怎么用

  • 在早期药物研发中,若样本量小且治疗组间不平衡,可考虑采用期中分析适应性设计来评估生物标志物的预测效应。

局限性

  • 原文未明确报告模拟研究的具体样本量、效应值、I类错误率数值及效能增益幅度。
  • 生物标志物分布未知的影响虽被考虑,但原文未给出具体处理结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biomarker identification plays a crucial role in precision medicine, where treatments are tailored to patients' intrinsic factors. Predictive biomarkers can be used to identify patients who are more likely to benefit from a treatment. However, identifying and validating such biomarkers pose substantial statistical and practical challenges, especially in the small sample setting. Several methods have been proposed for assessing whether a biomarker has a predictive effect, including the Average Kolmogorov-Smirnov Approach (AKSA), which has been shown to have improved operating characteristics for inference compared to alternative approaches. Yet power remains limited when sample sizes are small and unbalanced across treatment arms. Power can be improved through adaptive enrichment of the sample size, especially when treatment arms are small and unbalanced. We propose an adaptive design to improve power for detecting a predictive effect when sample sizes are small. Existing adaptive biomarker designs largely focus on enrichment of the trial, for example, adjusting enrolment criteria based on an assessment of the treatment-biomarker interaction at interim, or refining the biomarker threshold used to segregate the population into biomarker positive or negative (i.e., those patients more or less likely to respond to the treatment). Few designs explicitly address the task of formally declaring a predictive effect of a biomarker using an interim analysis. The interim analysis framework enables a more reliable assessment of a biomarker's predictive effect by introducing a pre-planned evaluation at the originally intended sample size of a study which may otherwise be underpowered due to the limited number of patients. Based on the interim results, the trial may (i) already have sufficient evidence to declare a biomarker as predictive, (ii) be terminated early due to a clear lack of evidence for a predictive effect, or (iii) enter an "expansion phase", where additional cohort of patients are recruited to improve the power for final analysis. The proposed framework addresses key methodological challenges, including interim decision rules, determining the magnitude and allocation of post-interim sample size increases, controlling the Type I error rate, and achieving meaningful gains in statistical power at the final analysis. The impact of an unknown biomarker distribution is also considered. These challenges are explored through simulation studies, where properties of the interim and final analyses are presented under various design configurations (where the decision bounds and size of the expansion are altered) and scenarios, in which the true predictive and prognostic effects of the biomarker are varied. Evaluated metrics include statistical power, Type I error control, and interim decision characteristics. The results inform the design of trials incorporating interim analyses to assess the predictive effect of a biomarker, enabling statistically efficient and well-calibrated decision-making.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Daniells L, Geronimi J, Hadjur H, et al. Adaptive Trial Designs for Assessing Predictiveness of a Biomarker in Early Phase Drug Development. Stat Med. 2026. PMID: 42706943. doi:10.1002/sim.70719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。